CompletedPhase 4NCT05426148
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Principal Investigator
- Yuemei HuJiangsu Provincial Center for Disease Prevention and Control
- Intervention
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®(biological)
- Enrollment
- 540 target
- Eligibility
- 9-14 years · FEMALE
- Timeline
- 2020 – 2021
Study locations (1)
- Dongtai City Center for Disease Control and Prevention Dongtai, Jiangsu, Dongtai, Jiangsu, China
Collaborators
Jiangsu Province Centers for Disease Control and Prevention · Dongtai City Centers for Disease Control and Prevention
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05426148 on ClinicalTrials.gov